Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt), also known as pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin, is highly overexpressed in many types of tumors, which makes it a great target for chemotherapy. Recent studies also suggest that Nampt plays a role in improving immune functions. University of Pittsburgh researchers have synthesized and tested a novel class of Nampt inhibitors in a current study, which shows that they have exhibited excellent potency and ADME properties.